{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T01:47:47Z","timestamp":1777772867179,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transcatheter edge to edge repair (TEER) improves prognosis in patients with functional mitral regurgitation (FMR) receiving guideline directed medical therapy (GDMT). Many patients with FMR do not receive GDMT and the utility of TEER in this population remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively studied patients undergoing TEER. Clinical, echocardiographic and procedural variables were recorded. GDMT was defined as use of RAAS inhibitors and MRAs unless GFR was under 30 as well as beta blockers. The primary endpoint of the study was one year mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>168 patients (mean age 71.3\u2009\u00b1\u20099.3; 66% males) with FMR who underwent TEER were included of whom 116 (69%) received GDMT at the time of TEER and 52 (31%) did not. There were no significant demographic or clinical differences between the groups. There were no significant differences in procedural success and complications between groups. One year mortality was identical in the two groups (15% vs. 15%; RR 1.06, CI 0.43\u20132.63, P\u2009=\u20090.90).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that procedural success and one year mortality following TEER was not significantly different in HFREF patients with FMR with or without GDMT. Larger, prospective studies are necessary to define the benefit of TEER in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-023-03344-2","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T15:02:49Z","timestamp":1686927769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes following transcatheter repair in patients with functional mitral regurgitation not receiving guideline directed medical therapy in Israel"],"prefix":"10.1186","volume":"23","author":[{"given":"David","family":"Leibowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorel","family":"Goland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronen","family":"Beeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Planer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Kutsher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Hasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mony","family":"Shuvy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"3344_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jacc.2015.02.009","volume":"65","author":"AW Asgar","year":"2015","unstructured":"Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis and therapeutic considerations. J Am Coll Cardiol. 2015;65:1231\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"3344_CR2","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamacardio.2017.2976","volume":"2","author":"A Sannino","year":"2017","unstructured":"Sannino A, Smith RL II, Schiattarella GG, Trimarco B, Esposito G, Grayburn PA. Survival and cardiovascular outcomes of patients with secondary mitral regurgitation: a systematic review and meta-analysis. JAMA Cardiol. 2017;2:1130\u20139.","journal-title":"JAMA Cardiol"},{"key":"3344_CR3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld JA, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ. COAPT investigators. Transcatheter mitral-valve repair in patients with heart failure. N Eng J Med. 2018;379:2307\u201318.","journal-title":"N Eng J Med"},{"key":"3344_CR4","first-page":"727","volume":"22","author":"A Vahanian","year":"2021","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, J\u00fcni P, Pierard L, Prendergast BD, S\u00e1daba JR, Tribouilloy C, Wojakowski W, ESC\/EACTS Scientific Document Group. 2021ESC\/EACTS guidelines for the management of valvular heart disease. Eur J Cardiovasc Surg. 2021;22:727\u2013800.","journal-title":"Eur J Cardiovasc Surg"},{"key":"3344_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/clc.23664","volume":"144","author":"PA McCullough","year":"2021","unstructured":"McCullough PA, Mehta HS, Barker CM, Van Houten J, Mollenkopf S, Gunnarsson C, Ryan M, Cork DP. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction. Clin Cardiol. 2021;144:1192\u20138.","journal-title":"Clin Cardiol"},{"key":"3344_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Green","year":"2018","unstructured":"Green SJ, Butler J, Albert AM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF. Fonarow GC. Medical therapy for heart failure with reduced ejection fraction the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"3344_CR7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","volume":"73","author":"SJ Green","year":"2019","unstructured":"Green SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:2365\u201383.","journal-title":"J Am Coll Cardiol"},{"key":"3344_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.510","volume":"18","author":"M Komadja","year":"2016","unstructured":"Komadja M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L, QUALIFY Investigators. Physicians adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514\u201322.","journal-title":"Eur J Heart Fail"},{"key":"3344_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/ije\/dyl012","volume":"35","author":"JD Kark","year":"2006","unstructured":"Kark JD, Fink R, Adler B, Goldberger N, Goldman S. The incidence of coronary heart disease among Palestinians and Israelis in Jerusalem. Int J Epidemiol. 2006;35:448\u201357.","journal-title":"Int J Epidemiol"},{"key":"3344_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1472-6963-9-130","volume":"9","author":"J Perelman","year":"2009","unstructured":"Perelman J, Shmueli A, McDonald KM, Pilote L, Saynina O, Closon M-C, Investigators TECH. Inequality in treatment use among elderly patients with acute myocardial infarction: USA, Belgium and Quebec. BMC Health Serv Res. 2009;9:130.","journal-title":"BMC Health Serv Res"},{"key":"3344_CR11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/eurheartj\/ehi251","volume":"26","author":"M Komajda","year":"2005","unstructured":"Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson P, Le Pen C. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26:1653\u20139.","journal-title":"Eur Heart J"},{"key":"3344_CR12","doi-asserted-by":"publisher","first-page":"e002606","DOI":"10.1161\/JAHA.115.002606","volume":"5","author":"TM Ruppar","year":"2016","unstructured":"Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. J Am Heart Assoc. 2016;5:e002606.","journal-title":"J Am Heart Assoc"},{"key":"3344_CR13","doi-asserted-by":"crossref","unstructured":"Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J. 2002 Sep;144:524\u20139.","DOI":"10.1067\/mhj.2002.123575"},{"key":"3344_CR14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/eurheartj\/ehab086","volume":"42","author":"AJS Coats","year":"2021","unstructured":"Coats AJS, Anker SD, Baumbach A, Alfieri O, von Bardeleben RS, Bauersachs J, Bax JJ, Boveda S, Celutkiene_J Cleland JG, Dagres N, Deneke T, Farmakis D, Filippatos G, Hausleiter J, Hindricks G, Jankowska EA, Lainscak M, Leclercq C, Lund LH, McDonagh T, Mehra MR, Marco Metra M, Mewton N, Mueller C, Mullens W, Muneretto C, Obadia JF, Ponikowski P, Praz F, Rudolph V, Ruschitzka F, Vahanian A, Windecker S, Zamorano JL, Edvardsen T, Heidbuchel H, Seferovic PM, Prendergast B. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the heart failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J. 2021;42:1254\u201369.","journal-title":"Eur Heart J"},{"key":"3344_CR15","doi-asserted-by":"publisher","first-page":"e004346","DOI":"10.1161\/CIRCEP.116.004346","volume":"9","author":"NA Chatterjee","year":"2016","unstructured":"Chatterjee NA, Gold MR, Waggoner AD, Picard MH, Stein KM, Yu Y, Meyer TE, Wold N, Ellenbogen KA, Singh JP. Longer left ventricular electric delay reduces mitral regurgitation after cardiac resynchronization therapy. Circ Arrhythm Electrophysiol. 2016;9:e004346.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"3344_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","volume":"23","author":"GMC Rosano","year":"2021","unstructured":"Rosano GMC, Moura B, Metra M, B\u00f6hm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, \u010celutkien\u0117 J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the heart failure association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:872\u201381.","journal-title":"Eur J Heart Fail"},{"key":"3344_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCOUTCOMES.109.879478","volume":"3","author":"PN Peterson","year":"2010","unstructured":"Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA, American Heart Association Get With The Guidelines-Heart Failure Program. Treatment and risk in Heart failure: gaps in evidence or quality. Circ Cardiovasc Qual Outcomes. 2010;3:309\u201315.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3344_CR18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jama.294.10.1240","volume":"294","author":"DS Lee","year":"2005","unstructured":"Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240\u20137.","journal-title":"JAMA"},{"key":"3344_CR19","doi-asserted-by":"crossref","unstructured":"Cox ZL, Zalawadiya SK, Simonato M, Redfors B, Zhou Z, Kotinkaduwa L, Zile MR, Udelson JE, Lim DS, Grayburn PA, Mack MJ, Abraham WT, Stone GW, Lindenfeld J. Guideline directed medical therapy tolerability in patients with heart failure and mitral regurgitation: the COAPT trial. JACC Heart Fail 2023 Apr 21:S2213-1779(23)00139-7.","DOI":"10.1016\/j.jchf.2023.03.009"},{"key":"3344_CR20","doi-asserted-by":"crossref","unstructured":"Adamo M, Tomasoni D, Stolz L, Stocker TJ, Pancaldi E, Koell B, Karam N, Besler C, Giannini C, Sampaio F, Praz F, Ruf T, Pechmajou L, Neuss M, Iliadis C, Baldus S, Butter C, Kalbacher D, Lurz P, Melica B, Petronio AS, von Stephan R, Windecker S, Butler J, Fonarow GC, Hausleiter J, Metra M. Impact of transcatheter edge-to-edge mitral valve repair on guideline-directed medical therapy uptitration. JACC Cardiovasc Interv 2023 Apr 24; 16(8):896\u2013905.","DOI":"10.1016\/j.jcin.2023.01.362"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03344-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03344-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03344-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T15:05:44Z","timestamp":1686927944000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03344-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3344"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03344-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"17 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in all institutions under the ethical principles of Good Clinical Practice and in accordance with the Declaration of Helsinki. Patient participation in the database received approval by the institutional review board of all institutions. (Hadassah Medical Organization IRB number 72\u2009\u2212\u200918, most recent approval 24.4.22, Shaarei Tzedek Medical Center IRB number 261\u2009\u2212\u200918 most recent approval 1.2.22, Kaplan Medical Center IRB number 68-2010, most recent approval 17.2.22). All subjects provided informed consent for participation in the database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"304"}}